Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$1.54 USD
+0.07 (4.76%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.53 -0.01 (-0.65%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.54 USD
+0.07 (4.76%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.53 -0.01 (-0.65%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth D Momentum C VGM
Zacks News
Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -16.22% and -22.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)
by Zacks Equity Research
Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)
Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.
Here's Why You Can Buy Quest Diagnostics Stock Right Now
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.
Illumina Offers FDA-Approved NGS Cancer Companion Test Kit
by Zacks Equity Research
Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.
Lantheus Holdings at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.
Envision Healthcare (EVHC) Acquires Anesthesia Associates
by Zacks Equity Research
Envision Healthcare Corporation (EVHC), recently announced that it has acquired Connecticut based anesthesia physician group practice, Anesthesia Associates of New London, P.C.
Boston Scientific Rides on New Growth Plans amid Headwinds
by Zacks Equity Research
On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Abaxis (ABAX) Product Portfolio Strong, Competition Rife
by Zacks Equity Research
On Jun 28, we issued an updated research report on California-based Abaxis, Inc. (ABAX).
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
by Zacks Equity Research
On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.
Walgreens (WBA) Tops Q3 Earnings, Scraps Rite-Aid Deal
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.33 in third-quarter fiscal 2017, up 12.7% year over year.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)
by Zacks Equity Research
Medtronic plc (MDT) inked a new outcomes-based collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System.
Walgreens Boots-LabCorp Tie Up for Patient Service Centers
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA), a major pharmacy-led, health and wellbeing enterprise, recently announced collaboration with leading diagnostic service provider LabCorp (LH).
IDEXX Well-Poised on Strong Fundamentals, Global Growth
by Zacks Equity Research
On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
Quest Diagnostics to Buy Outreach Lab Service in Cape Cod
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.
Hologic (HOLX) Product Pipeline Strong, Competition Rife
by Zacks Equity Research
On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.
NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?
by Zacks Equity Research
On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes
by Zacks Equity Research
Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.
Penumbra (PEN) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.
3 Reasons Why Accelerate Diagnostics (AXDX) is a Great Momentum Stock
by Zacks Equity Research
Solid price performance both in short and long term makes Accelerate Diagnostics (AXDX) a Great Momentum Stock
ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System
by Zacks Equity Research
Medical technology company, ConforMIS, Inc. (CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.